Skip to main content
. 2022 Jul 12;36(5):573–589. doi: 10.1007/s40259-022-00544-8
Plants are becoming an accepted platform for the development of vaccine production.
A wide variety of human vaccine targets have been explored with promising outcomes.
Both influenza and SARS-CoV-2 have provided ideal opportunities to prove the applicability of the platform with encouraging results of plant-produced vaccines from phase III trials and authorisation for human use in Canada.